Purpose of review
The use of adeno-associated virus
(AAV) as an efficient, cardiotropic, and safe vector, coupled with the identification of key molecular targets, has placed gene-based therapies within reach of cardiovascular diseases. The purpose of this review is to provide a focused update on the current advances related to AAV-mediated gene therapy
in cardiovascular diseases, and particularly in heart failure
(HF), wherein gene therapy
has recently made important progress.
Multiple successful preclinical studies suggest a potential utility of AAV gene therapy
and biological heart pacing, as well as RNA overexpression. Moreover, AAV-mediated overexpression of several molecular targets involved in HF has demonstrated promising results in clinically relevant large animal models. In humans, a safe and successful completion of a phase 2 clinical trial targeting the sarcoplasmic reticulum calcium ATPase pump
with AAV has been reported. Serial studies are ongoing to further prove the efficacy of AAV-mediated sarcoplasmic reticulum calcium ATPase pump
gene transfer in human HF.
Significant progress in clinical translation of AAV-mediated cardiac gene therapy
has been achieved in recent years. This will prompt further clinical trials, and positive results could open a new era for cardiac gene therapy